Bionime Showcases RIGHTEST iFree 2 CGM at HIMSS 2026 in Las Vegas
Las Vegas, March 2026 — Bionime is participating in HIMSS 2026 at the Venetian Expo in Las Vegas, presenting its latest continuous glucose monitoring (CGM) solution, the RIGHTEST iFree 2 CGM.
At Booth #4265 on Level 2 of the Venetian Expo, Bionime is engaging with healthcare professionals and industry partners from March 10–12 to demonstrate how its CGM technology supports more informed clinical decisions and improved patient outcomes.
A central theme of Bionime’s presence at HIMSS 2026 is bridging the gap between medical hardware and digital health ecosystems. The RIGHTEST iFree 2 CGM is positioned as a solution designed to provide accurate glucose monitoring while integrating smoothly into connected care workflows, enabling both patients and providers to better interpret and act on glucose data.
As HIMSS 2026 draws to a close, Bionime continues to invite attendees to visit its booth for live demonstrations and discussions on the future of connected diabetes care. The company aims to address a critical question facing the healthcare industry: how to translate glucose data into meaningful, measurable improvements in patient health outcomes.